Frontiers in Ovarian Cancer Science

Preface -- Contents -- 1: Epidemiology and Etiology of Ovarian Cancer -- 1.1 Introduction -- 1.2 General Epidemiology of Ovarian Cancer -- 1.3 Current Status and Changes of Ovarian Cancer Incidence Rate -- 1.4 Current Status and Changes of Ovarian Cancer Mortality -- 1.5 International Comparison of Ovarian Cancer Incidence Rate and Mortality -- 1.6 Risk Factors for Ovarian Cancer -- References -- 2: Hereditary Ovarian Cancer -- 2.1 Introduction -- 2.2 Hereditary Breast and Ovarian Cancer (HBOC): BRCA-­Related Breast and Ovarian Cancer -- 2.2.1 Clinical and Molecular Features of HBOC -- 2.2.2 Ovarian Cancer Screening for Surveillance -- 2.2.3 Risk-Reducing Salpingo-Oophorectomy (RRSO) -- 2.2.4 Chemoprevention -- 2.3 Genes Other than BRCA1/2 Involved in Hereditary Ovarian Cancer -- 2.3.1 Mismatch Repair Genes (Lynch Syndrome) -- 2.3.2 Homologous Recombination Deficiency (HRD)-Related Genes -- 2.4 PARP Inhibitors -- References -- 3: Morphological and Molecular Pathogenesis of Epithelial Ovarian Tumors -- 3.1 Introduction -- 3.2 Representative Theories Related to the Morphological Pathogenesis of EOTs -- 3.2.1 The Theory of the Secondary Müllerian System -- 3.2.2 The Theory of Imported Disease -- 3.3 Two-Tiered Classification for Clinical, Morphological, and Molecular Pathogenesis -- 3.4 Morphological and Molecular Pathogenesis in Four Representative Malignant EOTs -- 3.4.1 Serous Carcinoma -- 3.4.1.1 High-Grade Serous Carcinoma -- 3.4.1.2 Low-Grade Serous Carcinoma -- 3.4.2 Endometrioid Carcinoma -- 3.4.3 Clear Cell Carcinoma -- 3.4.4 Mucinous Carcinoma -- References -- 4: Screening and Prevention of Ovarian Cancer -- 4.1 Introduction -- 4.2 Materials and Methods -- 4.2.1 Search Strategy and Selection Criteria -- 4.3 Results -- 4.3.1 The Systematic Literature Review.

4.3.2 Ovarian Cancer Screening in the General Population -- 4.3.2.1 CA125 -- 4.3.2.2 Transvaginal Sonography -- 4.3.2.3 Two-Stage Strategies -- 4.3.3 Ovarian Cancer Screening in the High-Risk Population -- 4.4 Prevention of Ovarian Cancer -- 4.4.1 Risk-Reducing Surgical Options -- 4.4.1.1 Risk-Reducing Salpingo-Oophorectomy (RRSO) -- 4.4.1.2 Risk-Reducing Oophorectomy (RRO) -- 4.4.1.3 Risk-Reducing Salpingectomy (RRS) -- 4.4.1.4 Tubal Ligation -- 4.4.2 Risk-Reducing Pharmacologic Options -- 4.5 Prevention of Breast Cancer -- 4.5.1 Risk-Reducing Surgical Options -- 4.5.2 Risk-Reducing Pharmacologic Options -- 4.6 Ovarian Cancer Screening in the Japanese Population -- 4.7 Discussion -- References -- 5: Pathology of Epithelial Ovarian Tumors -- 5.1 Introduction -- 5.2 Classification and Nomenclature of Epithelial Ovarian Tumors -- 5.3 Origin of Ovarian Epithelial Tumors -- 5.4 Serous Tumors -- 5.4.1 Benign Serous Tumors -- 5.4.2 Serous Borderline Tumor/Atypical Proliferative Serous Tumor -- 5.4.2.1 Usual Serous Borderline Tumor/Atypical Proliferative Serous Tumor -- 5.4.2.2 Micropapillary Variant Serous Borderline Tumor (Noninvasive Low-Grade Serous Carcinoma) -- 5.4.2.3 Serous Borderline Tumor with Microinvasive Components -- 5.4.2.4 Extraovarian Spread of Serous Borderline Tumor -- Peritoneal Implants -- Lymph Node Involvement -- 5.4.3 Serous Carcinoma -- 5.4.3.1 Low-Grade Serous Carcinoma -- 5.4.3.2 High-Grade Serous Carcinoma -- 5.5 Mucinous Tumors -- 5.5.1 Mucinous Cystadenoma/Adenofibroma -- 5.5.2 Mucinous Borderline Tumor/Atypical Proliferative Mucinous Tumor (MBT/APMT) -- 5.5.3 Mucinous Carcinoma -- 5.5.4 Mucinous Tumor with Mural Nodule -- 5.6 Endometrioid Tumors -- 5.6.1 Benign Endometrioid Tumor -- 5.6.2 Endometrioid Borderline Tumor/Atypical Proliferative Endometrioid Tumor.

5.6.3 Endometrioid Carcinoma -- 5.7 Clear Cell Tumors -- 5.7.1 Benign Clear Cell Tumor and Borderline Tumor -- 5.7.2 Clear Cell Carcinoma -- 5.8 Brenner Tumors -- 5.8.1 Benign Brenner Tumor -- 5.8.2 Borderline Brenner Tumor/Atypical Proliferative Brenner Tumor -- 5.8.3 Malignant Brenner Tumor -- 5.9 Seromucinous Tumors -- 5.9.1 Seromucinous Borderline Tumors -- 5.9.2 Seromucinous Carcinoma -- 5.10 Other Epithelial Tumors -- 5.10.1 Squamous Cell Carcinoma -- 5.10.2 Undifferentiated Carcinoma -- References -- 6: Pathology of Non-epithelial Ovarian Tumors -- 6.1 Introduction -- 6.2 Sex Cord-Stromal Tumors: Pure Stromal Tumors -- 6.2.1 Fibroma, Cellular Fibroma, and Fibrosarcoma -- 6.2.1.1 Clinical Features -- 6.2.1.2 Pathological Features -- 6.2.2 Thecoma -- 6.2.2.1 Clinical Features -- 6.2.2.2 Pathological Features -- 6.2.3 Sclerosing Stromal Tumor -- 6.2.4 Microcytic Stromal Tumor -- 6.2.4.1 Clinical Features -- 6.2.4.2 Pathological Features -- 6.3 Pure Sex Cord Tumors -- 6.3.1 Adult Granulosa Cell Tumor (AGCT) -- 6.3.1.1 Clinical Features -- 6.3.1.2 Pathological Features -- 6.3.2 Juvenile Granulosa Cell Tumor (JGCT) -- 6.3.2.1 Clinical Features -- 6.3.2.2 Pathological Features -- 6.3.3 Sex Cord Tumor with Annular Tubules (SCTAT) -- 6.3.3.1 Clinical Features -- 6.3.3.2 Pathological Features -- 6.4 Mixed Sex Cord-Stromal Tumors -- 6.4.1 Sertoli-Leydig Cell Tumor (SLCT) -- 6.4.1.1 Clinical Features -- 6.4.1.2 Pathological Features -- 6.5 Immature Teratoma -- 6.5.1 Clinical Features -- 6.5.2 Pathologic Features -- 6.6 Small Cell Carcinoma of Ovary, Hypercalcemic Type -- 6.6.1 Clinical Features -- 6.6.2 Pathological Features -- 6.6.3 Differential Diagnosis -- 6.7 Solid Pseudopapillary Neoplasm of the Ovary -- References -- 7: Ovarian Cancer Genome and Molecular Experimental Sciences -- 7.1 Introduction.

7.2 High-Grade Serous Ovarian Carcinoma -- 7.2.1 Germline Mutations in Ovarian Carcinoma -- 7.2.2 The Genomic Landscape of High-Grade Serous Ovarian Carcinoma -- 7.2.3 Experiments to Identify Origin of High-Grade Serous Ovarian Carcinoma -- 7.3 Ovarian Clear Cell Carcinoma -- 7.3.1 Gene Expression of Ovarian Clear Cell Carcinoma -- 7.3.2 DNA Methylation Analysis of Ovarian Clear Cell Carcinoma -- 7.3.3 Genetic Analyses of Ovarian Clear Cell Carcinoma -- 7.3.4 Role of ARID1A, PIK3CA, and IL6 in the Carcinogenesis of Ovarian Clear Cell Carcinoma -- 7.4 Ovarian Endometrioid Carcinoma -- 7.4.1 Genetic Analysis of Ovarian Endometrioid Carcinoma -- 7.4.2 Mouse Models of Ovarian Endometrioid Carcinoma -- 7.4.3 Microsatellite Instability (MSI) in Ovarian Endometrioid Carcinoma -- 7.4.4 Genetic Analysis of Synchronous Endometrial and Ovarian Carcinoma -- 7.5 Mucinous Ovarian Tumors -- 7.5.1 Origin of Mucinous Ovarian Tumors -- 7.5.2 Genetic Features of Mucinous Ovarian Tumors -- 7.6 Serous Borderline Tumor and Low-Grade Serous Ovarian Carcinoma -- References -- 8: Strategies for the Management of Epithelial Ovarian Cancer -- 8.1 Introduction -- 8.2 Surgical Management -- 8.2.1 Early (Localized to the Ovary)-Staged Ovarian Cancer -- 8.2.2 Advanced Stage (Stage II or More) Ovarian Cancer -- 8.2.3 Risk-Reducing Salpingo-Oophorectomy (RRSO) -- 8.2.4 Laparoscope-Assisted Surgery -- 8.2.5 Intraoperative Pathological Evaluation -- 8.3 Frontline Chemotherapy -- 8.3.1 Standard Chemotherapy -- 8.3.2 Intraperitoneal Chemotherapy -- 8.3.3 After Primary Treatment -- 8.4 Molecular Targeted Therapy -- 8.5 Optimal Follow-Up After Primary Treatment -- References -- 9: Strategies for the Management of Epithelial Ovarian Borderline Tumors -- 9.1 Introduction -- 9.2 Characteristics of Serous Borderline Tumor.

9.3 Characteristics of Mucinous Borderline Tumor and Seromucinous Borderline Tumor -- 9.4 Surgical Management of BOT -- 9.4.1 Standard Surgical Procedure -- 9.4.2 Laparoscopic Surgery and Restaging Surgery -- References -- 10: Strategies for the Management of Non-­epithelial Ovarian Tumors -- 10.1 Introduction -- 10.2 Ovarian Sex Cord-Stromal Tumors (SCSTs) -- 10.2.1 Clinical Features of Ovarian SCSTs -- 10.2.2 Molecular Aspects of Ovarian SCSTs -- 10.2.3 Treatment Strategy of Ovarian SCSTs -- 10.3 Malignant Ovarian Germ Cell Tumors (MOGCTs) -- 10.3.1 Clinical Features of MOGCTs -- 10.3.2 Molecular Aspects of Ovarian Germ Cell Tumors -- 10.3.3 Treatment Strategy of Ovarian Germ Cell Tumor -- 10.4 Conclusions and Future Directions -- References -- 11: Primary Surgical Treatment of Epithelial Ovarian Cancer -- 11.1 Introduction -- 11.2 Centralized Primary Care for Advanced Ovarian Cancer -- 11.3 Optimal Surgical Management of Ovarian Cancer Clinically Confined to the Ovary -- 11.4 Optimal Surgical Management of Clinical Stage II or More Advanced Ovarian Cancer -- 11.5 Neoadjuvant Chemotherapy (NAC) and Interval Debulking Surgery (IDS) -- 11.6 Lymph Node Metastasis in the New FIGO Ovarian Cancer Staging System (2014) [15] -- 11.7 Lymphadenectomy for Early Ovarian Cancer -- 11.8 Lymphadenectomy for Advanced Ovarian Cancer: Complete Dissection Versus Resection of Bulky Nodes -- 11.9 Can Interval Debulking Surgery (IDS) Be Recommended After Primary Debulking Surgery (PDS) with a Suboptimal Outcome? -- 11.10 Optimal Management for Preservation of Fertility -- 11.11 Surgery for Elderly Patients -- 11.12 Is Laparoscope-Assisted Surgery Possible? -- References -- 12: Primary Chemotherapy and Targeted Molecular Therapy of Epithelial Ovarian Cancer -- 12.1 Introduction -- 12.2 The History of Primary Chemotherapy.

12.3 An Alternative Primary Chemotherapy.

Medienart:	E-Book

Erscheinungsjahr:	2017
Erschienen:	Singapore: Springer Singapore ; 2017

Reihe:	Comprehensive Gynecology and Obstetrics Comprehensive Gynecology and Obstetrics Ser.

Sprache:	Englisch

Beteiligte Personen:	Katabuchi, Hidetaka [VerfasserIn]

Links:	Volltext [lizenzpflichtig]

ISBN:	978-981-10-4160-0

Themen:	Electronic books Reproductive Medicine

Umfang:	1 Online-Ressource (313 pages)

Förderinstitution / Projekttitel:

PPN (Katalog-ID):	897544374